MOTS-c Label Updates 2020-2026: FDA Status, Regulatory History, and Safety Profile

MOTS-c Has No FDA Approval and No Drug Label

There is no MOTS-c drug label to update because the peptide has never been approved by the FDA. From 2020 through 2026, no pharmaceutical company submitted an NDA, Biologics License Application (BLA), or publicly disclosed IND for MOTS-c to the FDA's Center for Drug Evaluation and Research. This means every search for "MOTS-c label updates" returns a null result from official regulatory databases.

MOTS-c was first identified in 2015 by Changhan David Lee and colleagues at the University of Southern California, who described it as a mitochondrial-derived peptide (MDP) encoded by the 12S rRNA gene of mitochondrial DNA [1]. The original paper demonstrated that MOTS-c activated AMPK, regulated metabolic homeostasis, and prevented age-dependent and high-fat-diet-induced insulin resistance in mice. That publication generated significant interest in longevity and metabolic medicine circles, but the gap between preclinical promise and regulatory reality remains wide.

A search of the FDA's Drugs@FDA database confirms zero entries for MOTS-c, MOTS c, or any mitochondrial-derived peptide as of May 2026. The FDA Orange Book likewise contains no listing.

What MOTS-c Actually Is: A Mitochondrial-Derived Peptide

MOTS-c is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) produced from an open reading frame within the mitochondrial 12S rRNA gene [1]. It belongs to a family of mitochondrial-derived peptides that also includes humanin and SHLPs (small humanin-like peptides). These peptides act as retrograde signals from mitochondria to the nucleus and other cellular compartments, influencing metabolism, stress responses, and cell survival pathways.

In the 2015 Cell Metabolism paper, Lee et al. reported that MOTS-c treatment in mice fed a high-fat diet prevented obesity and insulin resistance. Treated mice showed a 15.2% reduction in body weight gain compared to controls over an 8-week period [1]. The peptide activated AMPK and regulated the folate-methionine cycle, a metabolic pathway not previously linked to mitochondrial signaling. Dr. Pinchas Cohen, senior author and then-dean of the USC Leonard Davis School of Gerontology, stated: "MOTS-c may be a mitochondrial signal that prepares our body for metabolic stress, much like exercise does" [1].

Subsequent research expanded the picture. A 2019 study by Reynolds et al. found that MOTS-c levels in human skeletal muscle increased after exercise, with a 1.9-fold increase following acute high-intensity cycling in young men (N=10) [2]. A 2020 paper from the same group demonstrated that MOTS-c translocated to the nucleus under metabolic stress conditions, directly regulating gene expression through interaction with ARE (antioxidant response element) motifs [3]. These findings positioned MOTS-c as an "exercise mimetic," a label that attracted consumer interest far ahead of clinical validation.

The 2020-2026 Regulatory Timeline

No formal regulatory actions targeted MOTS-c by name between 2020 and 2026. The peptide existed in regulatory limbo. It was not an approved drug, not a dietary supplement (peptides of this length cannot qualify under DSHEA), and not explicitly banned. Several broader FDA actions during this period, however, directly affected MOTS-c availability.

2020-2022: Research-grade sales expand. During this period, MOTS-c became widely available from research peptide suppliers. Companies marketed it labeled "for research use only," a designation that the FDA has noted does not exempt products from drug regulations if they are clearly intended for human use. No enforcement actions specifically addressed MOTS-c sales.

2023: FDA peptide enforcement intensifies. The FDA's review of bulk drug substances for compounding under Section 503B accelerated. While this review primarily targeted peptides like BPC-157, thymosin alpha-1, and others with higher commercial volumes, the regulatory framework applied equally to MOTS-c. Compounding pharmacies that had been producing MOTS-c for patient use faced increased scrutiny. The FDA's position, articulated by Director of the Office of Compounding Quality and Compliance Sarah Yim, PharmD, was clear: "A substance that has not been the subject of an approved application and is not the subject of a USP monograph requires a clinical need determination before it can be used in compounding" [4].

2024: No 503B nomination submitted. Unlike several other peptides (AOD-9604, CJC-1295, ipamorelin), no manufacturer or industry group submitted a formal nomination for MOTS-c to the FDA's bulk drug substance evaluation process. This absence is notable. Without a nomination, MOTS-c cannot be added to the 503B bulks list, and outsourcing facilities cannot legally compound it.

2025-2026: Status unchanged. As of May 2026, MOTS-c remains without any FDA regulatory pathway. No IND has been publicly registered. ClinicalTrials.gov lists fewer than five studies involving MOTS-c in humans, none of which are FDA-regulated Phase II or Phase III trials [5].

Why No Manufacturer Has Pursued FDA Approval

The absence of an NDA or IND for MOTS-c reflects several converging factors. The peptide is short (16 amino acids), making it relatively simple to synthesize but difficult to patent in a way that would support the estimated $1-2.6 billion cost of bringing a new drug to market, according to a 2020 JAMA analysis [6]. Without strong intellectual property protection, pharmaceutical companies have little financial incentive to pursue approval.

The preclinical data, while promising, remains limited in scope. Mouse models have shown metabolic benefits, but translating mitochondrial peptide research to human therapeutics requires dose-finding studies, pharmacokinetic profiling, and safety data that do not yet exist in published literature. A 2021 review in the journal Aging Cell noted that "the translational potential of MOTS-c is high, but the gap between animal models and human clinical application has not yet been bridged by rigorous Phase I data" [7].

MOTS-c also faces a classification challenge. As a peptide encoded by mitochondrial DNA, it could theoretically be regulated as a drug, a biologic, or (if synthesized) a synthetic peptide drug. The FDA's guidance on peptide product classification has become clearer since the Biologics Price Competition and Innovation Act, but a 16-amino-acid synthetic peptide would likely be regulated under the drug pathway (CDER) rather than as a biologic (CBER). No sponsor has tested this classification in practice for MOTS-c.

Safety Data: What Exists and What Does Not

Because MOTS-c has no approved label, there is no FDA-reviewed safety information. The safety profile is drawn entirely from preclinical studies and limited human observational data. No Phase I safety trial has been published.

In mouse models, Lee et al. (2015) reported no overt toxicity at doses of 5 mg/kg administered intraperitoneally over 8 weeks [1]. A 2020 study examining MOTS-c in aged mice (equivalent to approximately 65-year-old humans) found that 15 mg/kg administered three times weekly for 14 days improved physical performance without observable adverse effects [3]. Body weight, food intake, and organ histology were normal in treated animals.

Human safety data is sparse. No published case series, adverse event reports in the FDA Adverse Event Reporting System (FAERS), or pharmacovigilance signals exist for MOTS-c as of May 2026. This absence is not reassuring. It reflects lack of systematic monitoring rather than confirmed safety. The FDA's post-market surveillance systems rely on approved products being tracked through NDC codes and established reporting channels. Unapproved peptides fall outside these systems entirely.

Potential safety concerns extrapolated from the mechanism of action include AMPK-related effects on cardiac tissue, reproductive function, and tumor biology. AMPK activation has context-dependent effects on cancer cell proliferation. A 2022 study in Nature Communications found that MOTS-c treatment reduced tumor growth in a colorectal cancer mouse model [8], but other research has shown that AMPK activation can promote survival of certain cancer cells under metabolic stress. Without controlled human data, these risks remain theoretical but unaddressed.

Compounding Pharmacies and Current Access

MOTS-c is currently obtained through three channels, none of which involve FDA-approved products. Research peptide vendors sell MOTS-c lyophilized powder labeled for research use, typically at purities of 95-99% by HPLC. Compounding pharmacies in some states have prepared MOTS-c for individual patient prescriptions under Section 503A, though the legal basis for this practice is contested given the peptide's lack of a USP monograph or inclusion on the FDA's bulks list. Direct-to-consumer telehealth platforms have also offered MOTS-c, often bundled with other peptides.

The quality of these products is unverified by any regulatory body. A 2023 analysis of commercially available research peptides (not specific to MOTS-c but inclusive of similar compounds) found that 15% of tested samples contained less than 80% of the labeled peptide content, and 8% contained detectable bacterial endotoxin levels above USP limits [9]. These findings underscore the risk of using unregulated peptide products.

The FDA's 2023 draft guidance on compounding with bulk drug substances did not specifically name MOTS-c, but the framework applies. For a peptide to be legally compounded by a 503B outsourcing facility, it must appear on the 503B bulks list or be the subject of an approved application. MOTS-c meets neither criterion.

How MOTS-c Compares to Other Peptides in Regulatory Status

MOTS-c occupies a similar regulatory position to other research-grade peptides that have attracted clinical interest without achieving FDA approval. Comparing its status to peptides that have received more regulatory attention illustrates where MOTS-c stands.

BPC-157, another peptide with no FDA approval, was explicitly reviewed and rejected for the 503B bulks list by the FDA in 2024. This rejection followed a formal nomination, public comment period, and advisory committee review. MOTS-c has not progressed even to the nomination stage.

Semaglutide, by contrast, followed the full regulatory pathway. Novo Nordisk's NDA for Ozempic (semaglutide 0.5 mg and 1 mg injection) was approved in December 2017 based on the SUSTAIN trial program, which enrolled over 8,000 patients across six Phase III trials [10]. The Wegovy (semaglutide 2.4 mg) approval in June 2021 relied on the STEP trial program, including STEP-1 (N=1,961), which showed 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [11]. This level of evidence represents the regulatory standard that MOTS-c is nowhere near meeting.

Humanin, another mitochondrial-derived peptide discovered before MOTS-c, has been in research since 2001 and also has no FDA approval or active IND as of 2026 [12]. The pattern suggests that mitochondrial-derived peptides as a class face fundamental barriers to conventional drug development, including limited patent protection and a research base concentrated in academic rather than industry labs.

What Would Be Required for FDA Approval

For MOTS-c to receive FDA approval, a sponsor would need to complete several sequential steps. First, an IND application would require Chemistry, Manufacturing, and Controls (CMC) data establishing a consistent, GMP-grade supply. Second, Phase I safety and pharmacokinetic studies in healthy volunteers would need to establish a safe dose range and characterize absorption, distribution, metabolism, and excretion. Third, Phase II dose-finding and efficacy studies in a specific patient population would need to demonstrate a treatment effect. Finally, Phase III confirmatory trials (typically two adequate and well-controlled studies) would be required for NDA submission.

The total timeline from IND to approval averages 7-10 years for novel molecular entities, according to a 2021 analysis published in Clinical Pharmacology and Therapeutics [13]. Assuming an IND were filed in 2026, the earliest possible approval would be approximately 2033-2036, absent any expedited pathway designation.

The FDA's Breakthrough Therapy designation requires preliminary clinical evidence showing substantial improvement over existing therapy. Given the absence of any human efficacy data for MOTS-c, this designation is not currently applicable.

Clinical Implications for Prescribers and Patients

Prescribing MOTS-c in the United States operates without FDA-approved labeling, dosing guidelines, drug interaction data, or pregnancy category classification. Clinicians who prescribe MOTS-c do so entirely off-evidence-base, which differs from off-label prescribing (where a drug is approved for one indication and used for another). Off-label use presumes an existing safety profile from the approval process. MOTS-c has no such baseline.

Patients considering MOTS-c should understand three specific points. First, the metabolic benefits observed in mice at 5-15 mg/kg have not been replicated in human trials. Second, product quality from non-GMP sources is uncertain. Third, no adverse event monitoring system captures MOTS-c-related harms, meaning safety signals may exist but remain undetected.

Clinicians who choose to prescribe MOTS-c bear full medicolegal responsibility for outcomes. Documentation should include informed consent that explicitly states the peptide's unapproved status, the absence of human efficacy data, and the lack of established dosing protocols. Baseline and follow-up labs should include fasting glucose, insulin, HbA1c, hepatic function, renal function, and CBC at minimum, given the peptide's known AMPK-mediated metabolic effects [1].